Advertisement
Screener

NeoGenomics, Inc. (NEO) Operating Lease Right-of-Use Assets

2.8 / 5 stars · 68/120 Roast Me

NeoGenomics, Inc. Operating Lease Right-of-Use Assets

NeoGenomics, Inc. (NEO) had Operating Lease Right-of-Use Assets of $78.61 million as of 2026-06-30, per its 10-Q filed 2026-07-28.

Financial Statements › Balance Sheet › Assets › Assets, Noncurrent

us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-07-28

  • 2026-06-30: Operating Lease, Right-of-Use Asset $78.61M.
  • 2026-03-31: Operating Lease, Right-of-Use Asset $76.70M.
  • 2025-12-31: Operating Lease, Right-of-Use Asset $78.44M.
  • 2025-09-30: Operating Lease, Right-of-Use Asset $80.15M.
Period endOperating Lease, Right-of-Use Asset
2026-06-30$78.61M
10-Q · filed 2026-07-28
2026-03-31$76.70M
10-Q · filed 2026-04-28
2025-12-31$78.44M
10-Q · filed 2026-07-28
2025-09-30$80.15M
10-Q · filed 2025-10-28
2025-06-30$82.87M
10-Q · filed 2025-07-29
2025-03-31$77.80M
10-Q · filed 2025-04-29
2024-12-31$79.58M
10-K · filed 2026-02-17
2024-09-30$81.44M
10-Q · filed 2024-11-05
2024-06-30$83.67M
10-Q · filed 2024-07-30
2024-03-31$86.58M
10-Q · filed 2024-04-30
2023-12-31$91.77M
10-K · filed 2025-02-18
2023-09-30$87.13M
10-Q · filed 2023-11-06
2023-06-30$91.41M
10-Q · filed 2023-08-08
2023-03-31$93.78M
10-Q · filed 2023-05-09
2022-12-31$96.11M
10-K · filed 2024-02-20
2022-09-30$98.94M
10-Q · filed 2022-11-08
2022-06-30$99.92M
10-Q · filed 2022-08-09
2022-03-31$101.95M
10-Q · filed 2022-05-09
2021-12-31$102.20M
10-K · filed 2023-02-24
2021-09-30$102.31M
10-Q · filed 2021-11-04
2021-06-30$54.56M
10-Q · filed 2021-08-09
2021-03-31$50.90M
10-Q · filed 2021-05-06
2020-12-31$45.79M
10-K · filed 2022-02-25
2020-09-30$45.86M
10-Q · filed 2020-10-29
2020-06-30$47.55M
10-Q · filed 2020-07-31
2020-03-31$49.08M
10-Q · filed 2020-04-29
2019-12-31$26.49M
10-K · filed 2021-02-25
2019-09-30$25.80M
10-Q · filed 2019-11-13
2019-06-30$26.06M
10-Q · filed 2019-08-07
2019-03-31$19.73M
10-Q · filed 2019-05-08
2019-01-01$9.70M
10-K · filed 2020-02-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
20/20 Biolabs, Inc. (AIDX)United States$0.005B